Skip to main content
. Author manuscript; available in PMC: 2022 Mar 14.
Published in final edited form as: J Biophotonics. 2021 May 4;14(7):e202100073. doi: 10.1002/jbio.202100073

Figure 4.

Figure 4.

The low and medium dose-treated scars in (groups 1 and 2) showed greater improvements in observer rating from baseline to 6 months compared to the control scars. (A) In Group 1 (low dose), the treated scars showed a 45.5% improvement from baseline to 6 months compared to 24.2% for the control scar. (B) In Group 2 (medium dose), the treated scars showed a 57.9% improvement from baseline to 6 months compared to no improvement for the control scars.